← Back to headlines
Eli Lilly's Experimental Drug Reduces Lung Cancer Recurrence Risk
Eli Lilly's experimental cancer drug has shown promise in reducing the risk of recurrence in patients with early-stage lung cancer.
19 Feb, 18:30 — 19 Feb, 18:30
Sources
Showing 1 of 1 sources
Related Stories
Study Suggests Syphilis-Like Disease Spread in Ancient Vietnam, Challenging Columbus Theory
just now
Padel for Parkinson’s Cycling Event Held at University of Ghana for Awareness
18m ago
Understanding and Managing Postpartum Sweating
29m ago
Protecting Dogs from Viper Bites as Warmer Weather Arrives
42m ago